Benzinga | Nov 2, 2021 10:58AM EDT

Myriad Genetics Q1 Adj. EPS $(0.02), Inline, Sales $167.30M Beat $165.04M Estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 86.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $167.30 million which beat the analyst consensus estimate of $165.04 million by 1.37 percent. This is a 15.22 percent increase over sales of $145.20 million the same period last year.